Status: Recruiting
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Participants needed: 37
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jul 16, 2026Locations: 1
Eligibility criteria
Unresectable thymoma or thymic carcinoma. [+19]
Is currently participating and receiving study therapy or has participated in a... [+17]